Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized open-label phase II study of SG1001 tablets in invasive fungal disease
CTR20252293Phase 2Active
- Sponsor
- Xianggen Biology
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SG1001 in invasive aspergillosis (IA), invasive mycoses, sponsored by Xianggen Biology. Started Jul 2025; status: active.
02
Drugs
SG1001
03
Conditions
invasive aspergillosis (IA)invasive mycoses
Beyond the preview
Go deeper on CTR20252293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252293.